BridgeMD
New treatment option for Digestive System Disease
Official title Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)
ClinicalTrials.gov ID: NCT05066139
What this study is testing
- What it's testing
- This is a monocentric, comparative, open-label, randomized parallel group study enrolling elderly subjects hospitalized in Strasbourg Europe Cancerology Institute (ICANS), starting chemotherapy or targeted therapy for the treatment of digestive cancer.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 75 and older
You may be able to join if
- Patients must be ≥ 75 years old
- Performance status 0, 1 or 2
- Diagnostic of digestive cancer, all stages (adjuvant or metastatic), with an indication for chemotherapy treatment or targeted therapy for a...
- Patients previously treated with one or several lines of chemotherapy for this digestive cancer are eligible
- Estimated life expectancy ≥ 3 months
You likely can't join if
- History of differentiated neuroendocrine tumors grade 1 or 2 (pancreas, small intestine)
- Cancer currently being treated (except for hormone therapy) other than current digestive cancer
- History of major surgery and/or curative radiation therapy during the last 4 weeks before inclusion
- Patients unable to submit to medical follow-up for geographical, social or psychological reasons
- Patients placed under guardianship
See the full eligibility criteria
- Patients must be ≥ 75 years old
- Performance status 0, 1 or 2
- Diagnostic of digestive cancer, all stages (adjuvant or metastatic), with an indication for chemotherapy treatment or targeted therapy for a treatment period of 24 weeks or more
- Patients previously treated with one or several lines of chemotherapy for this digestive cancer are eligible
- Estimated life expectancy ≥ 3 months
- Patients able to speak, read and understand French
- Signed informed consent from the patient
- Patients must have a social security coverage
- History of differentiated neuroendocrine tumors grade 1 or 2 (pancreas, small intestine)
- Cancer currently being treated (except for hormone therapy) other than current digestive cancer
- History of major surgery and/or curative radiation therapy during the last 4 weeks before inclusion
- Patients unable to submit to medical follow-up for geographical, social or psychological reasons
- Patients placed under guardianship
The study team makes the final eligibility decision.
Where it's taking place
- Strasbourg, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 75 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Strasbourg, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.